|
業務類別
|
Biotechnology |
|
業務概覽
|
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a singleoperating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease. |
| 公司地址
| 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540 |
| 電話號碼
| +1 415 573-3220 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kardigan.bio |
| 員工數量
| 380 |
| Mr. John B. Moriarty, J.D.,Jr |
Chief Legal Officer and Corporate Secretary |
-- |
26/05/2026 |
| Mr. Andy Pasternak |
Chief Strategy Officer |
-- |
26/05/2026 |
| Mr. Tassos Gianakakos |
Chairman of the Board and Chief Executive Officer |
-- |
26/05/2026 |
| Ms. Brianne Puglisi |
Chief Financial Officer and and Principal Accounting Officer |
-- |
26/05/2026 |
| Dr. Jay Edelberg, M.D.,PhD |
Chief Medical Officer |
-- |
26/05/2026 |
|
|
| Dr. David P. Meeker,M.D. |
Independent Director |
26/05/2026 |
| Mr. Douglas E. Giordano, M.B.A. |
Independent Director |
26/05/2026 |
| Ms. Kimberly J. Popovits |
Independent Director |
26/05/2026 |
| Mr. Paul L. Berns |
Independent Director |
26/05/2026 |
| Mr. Timothy P. Walbert |
Independent Director |
26/05/2026 |
| Mr. Tassos Gianakakos |
Chairman of the Board and Chief Executive Officer |
26/05/2026 |
|
|
|
|
